Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMMUNOMEDICS CEA-SCAN COLORECTAL CANCER IMAGING AGENT REVIEW DEFERRED BY FDA CMTE.; CLINICAL UTILITY MAY BE TOO DIFFICULT TO ASSESS FOR DIAGNOSTICS

This article was originally published in The Gray Sheet

Executive Summary

The review of Immunomedics' monoclonal antibody-based CEA-Scan product license application for imaging in colorectal cancers was postponed by FDA's Oncologic Drugs Advisory Committee on Oct. 17 until FDA and the sponsor resolve issues concerning analyses and data to be presented to the committee.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel